Skip to Navigation Skip to Content Skip to Footer

Microbiology Logo Microbiology & Immunology
Te Tari Moromoroiti me te Ārai Mate

Dr Paulo Urbano

Current research:

During the past years, I have been working in different fields in Biomedicine. From experimental arthritis, biotechnology manufacturing processes of biological drugs and liposomes and clinical trial coordinator (Brazil) to current translational medicine, focusing in clinical immunology. I'm a specialist in flow cytometry, a tool that has been shown to be indispensable in my routine for immune profiling of patients suffering from inflammatory bowel diseases (IBD) and psoriasis and treated with anti-TNF agents (The Netherlands). I’m also interested in exploring new ways to classify diseases, where patients will be clustered and stratified based on molecular profile, rather than clinical manifestation, allowing the development of better, efficient and sophisticated treatments.

At the University of Otago, I'm studying the application of human organoids (stem cell-derived “mini-organs” in vitro) for personalised therapy. I believe that scientist must have a state in which there is overly excited restless with the questions surrounding the biology of the human condition. I’m always an enthusiastic researcher, highly motivated to contribute to the expansion of knowledge (in academia or company) with potential benefits for the society, which by the way, is the motive power that allows me to step forward for new challenges.


Urbano, P. C. M., He, X., van Heeswijk, B., Filho, O. P. S., Tijssen, H., Smeets, R. L., … Koenen, H. J. P. M. (2020). TNFα-signaling modulates the kinase activity of human effector Treg and regulates IL-17A expression. Frontiers in Immunology10, 3047.  doi: 10.3389/fimmu.2019.03047

Urbano, P. C. M., Koenen, H. J. P. M., Joosten, I., & He, X. (2018). An autocrine TNFα-tumor necrosis factor receptor 2 loop promotes epigenetic effects inducing human Treg stability in vitroFrontiers in Immunology9, 573.  doi: 10.3389/fimmu.2018.00573

Urbano, P. C. M., Aguirre-Gamboa, R., Ashikov, A., van Heeswijk, B., Krippner-Heidenreich, A., Tijssen, H., … Koenen, H. J. P. M. (2018). TNF-α–induced protein 3 (TNFAIP3)/A20 acts as a master switch in TNF-α blockade–driven IL-17A expression. Journal of Allergy & Clinical Immunology142(2), 517-529. doi: 10.1016/j.jaci.2017.11.024

Landman, S., Cruijsen, M., Urbano, P. C. M., Huls, G., van Erp, P. E. J., van Rijssen, E., … Koenen, H. J. P. M. (2018). DNA methyltransferase inhibition promotes Th1 polarization in human CD4+CD25highFOXP3+ regulatory T cells but does not affect their suppressive capacity. Journal of Immunology Research2018, 4973964.  doi: 10.1155/2018/4973964

Aguirre-Gamboa, R., Joosten, I., Urbano, P. C. M., van der Molen, R. G., van Rijssen, E., van Cranenbroek, B., … Koenen, H. J. P. M. (2016). Differential effects of environmental and genetic factors on T and B cell immune traits. Cell Reports17(9), 2474-2487.  doi: 10.1016/j.celrep.2016.10.053

Azevedo, V. F., Troiano, L. D. C., Galli, N. B., Kleinfelder, A., Catolino, N. M., & Urbano, P. C. M. (2016). Adalimumab: a review of the reference product and biosimilars. Biosimilars6, 29-44.  doi: 10.2147/BS.S98177

Azevedo, V. F., Galli, N., Kleinfelder, A., D’Ippolito, J., & Urbano, P. C. M. (2015). Etanercept biosimilars. Rheumatology International35(2), 197-209.  doi: 10.1007/s00296-014-3080-5

Urbano, P. C. M., Soccol, V. T., Teixeira, V. N., Oliveira, P. G., Filippin, L. I., Bonat, W. H., … Azevedo, V. F. (2015). Effect of pegylated phosphatidylserine-containing liposomes in experimental chronic arthritis. BMC Pharmacology & Toxicology16(1), 24.  doi: 10.1186/s40360-015-0022-0

Urbano, P. C. M., Soccol, V. T., & Azevedo, V. F. (2014). Apoptosis and the FLIP and NF-kappa B proteins as pharmacodynamic criteria for biosimilar TNF-alpha antagonists. Biologics8, 211-220. doi: 10.2147/BTT.S57253